TY - JOUR
T1 - Relationship between the inflammation and coagulation pathways in patients with severe sepsis
T2 - Implications for therapy with activated protein C
AU - Morris, Peter E.
AU - Hite, R. Duncan
AU - Ohl, Christopher
PY - 2002
Y1 - 2002
N2 - In patients with severe sepsis, thrombin has been implicated in the interrelationship between the coagulation and inflammation pathways. Thrombin is responsible for conversion of fibrinogen to fibrin (thrombus formation). Thrombin also activates endothelial cells, white blood cells and platelets. Regulation of both the coagulation and inflammation pathways is in part through the interaction of thrombin and activated protein C. Activated protein C has particular attributes that may inhibit microvascular thrombi, promote fibrinolysis and directly dampen the pro-inflammatory aspect of infection. In patients with severe sepsis, many investigators have demonstrated an active coagulopathic state, with low protein C levels. A phase III clinical trial has now demonstrated reduced mortality in patients with severe sepsis receiving activated protein C.
AB - In patients with severe sepsis, thrombin has been implicated in the interrelationship between the coagulation and inflammation pathways. Thrombin is responsible for conversion of fibrinogen to fibrin (thrombus formation). Thrombin also activates endothelial cells, white blood cells and platelets. Regulation of both the coagulation and inflammation pathways is in part through the interaction of thrombin and activated protein C. Activated protein C has particular attributes that may inhibit microvascular thrombi, promote fibrinolysis and directly dampen the pro-inflammatory aspect of infection. In patients with severe sepsis, many investigators have demonstrated an active coagulopathic state, with low protein C levels. A phase III clinical trial has now demonstrated reduced mortality in patients with severe sepsis receiving activated protein C.
UR - http://www.scopus.com/inward/record.url?scp=0036917329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036917329&partnerID=8YFLogxK
U2 - 10.2165/00063030-200216060-00002
DO - 10.2165/00063030-200216060-00002
M3 - Review article
C2 - 12463764
AN - SCOPUS:0036917329
SN - 1173-8804
VL - 16
SP - 403
EP - 417
JO - BioDrugs
JF - BioDrugs
IS - 6
ER -